These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23489260)

  • 1. Clinical significance of nucleophosmin/B23 and human epidermal growth factor receptor 2/neu expressions in gastric cancers.
    Zhou F; Qiu W; Sun L; Xiang J; Sun X; Sui A; Ding A; Yue L
    APMIS; 2013 Jul; 121(7):582-91. PubMed ID: 23489260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of nucleophosmin/B23 with bladder cancer recurrence based on immunohistochemical assessment in clinical samples.
    Tsui KH; Juang HH; Lee TH; Chang PL; Chen CL; Yung BY
    Acta Pharmacol Sin; 2008 Mar; 29(3):364-70. PubMed ID: 18298902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic Implications of Eukaryotic Initiation Factor 3f and Her-2/neu Expression in Gastric Cancer.
    Cheng Y; Zhou J; Li H
    Clin Transl Sci; 2015 Aug; 8(4):320-5. PubMed ID: 25684180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients.
    Liu W; Zhong S; Chen J; Yu Y
    J Clin Gastroenterol; 2012 Apr; 46(4):e31-7. PubMed ID: 22064554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Both high expression of nucleophosmin/B23 and CRM1 predicts poorer prognosis in human gastric cancer.
    Zhou F; Chen E; You D; Song Y; Sun Z; Yue L
    APMIS; 2016 Dec; 124(12):1046-1053. PubMed ID: 27714846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma.
    Tsui KH; Cheng AJ; Chang Pe; Pan TL; Yung BY
    Urology; 2004 Oct; 64(4):839-44. PubMed ID: 15491744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
    Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
    J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Association of HER-2/neu expression with prognosis of gastric cancer].
    Chen B; Luo RC; Cui F; Qian XY
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Mar; 26(3):344-7. PubMed ID: 16546744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
    Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
    Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic significance of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients.
    Al-Moundhri MS; Nirmala V; Al-Hadabi I; Al-Mawaly K; Burney I; Al-Nabhani M; Thomas V; Ganguly SS; Grant C
    J Surg Oncol; 2005 Sep; 91(4):243-52. PubMed ID: 16121348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leptin and HER-2 are associated with gastric cancer progression and prognosis of patients.
    Geng Y; Wang J; Wang R; Wang K; Xu Y; Song G; Wu C; Yin Y
    Biomed Pharmacother; 2012 Sep; 66(6):419-24. PubMed ID: 22883999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER-2/neu amplification is an independent prognostic factor in gastric cancer.
    Park DI; Yun JW; Park JH; Oh SJ; Kim HJ; Cho YK; Sohn CI; Jeon WK; Kim BI; Yoo CH; Son BH; Cho EY; Chae SW; Kim EJ; Sohn JH; Ryu SH; Sepulveda AR
    Dig Dis Sci; 2006 Aug; 51(8):1371-9. PubMed ID: 16868827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of TFF3 protein and Her-2/neu status in patients with gastric adenocarcinoma.
    Xu CC; Yue L; Wei HJ; Zhao WW; Sui AH; Wang XM; Qiu WS
    Pathol Res Pract; 2013 Aug; 209(8):479-85. PubMed ID: 23822993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of HER-2/neu expression in patients with ductal carcinoma in situ.
    Stackievicz R; Paran H; Bernheim J; Shapira M; Weisenberg N; Kaufman T; Klein E; Gutman M
    Isr Med Assoc J; 2010 May; 12(5):290-5. PubMed ID: 20929083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Her-2/neu and topoisomerase IIα in advanced breast cancer: a comprehensive FISH analysis of 245 cases.
    Engelstaedter V; Schiffers J; Kahlert S; Mainka P; Engel J; Kirchner T; Diebold J; Mayr D
    Diagn Mol Pathol; 2012 Jun; 21(2):77-83. PubMed ID: 22555090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
    Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma.
    Khan AJ; King BL; Smith BD; Smith GL; DiGiovanna MP; Carter D; Haffty BG
    Clin Cancer Res; 2002 Feb; 8(2):540-8. PubMed ID: 11839675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens.
    Yang J; Luo H; Li Y; Li J; Cai Z; Su X; Dai D; Du W; Chen T; Chen M
    Cell Biochem Biophys; 2012 Jan; 62(1):221-8. PubMed ID: 21927816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma.
    Riben MW; Malfetano JH; Nazeer T; Muraca PJ; Ambros RA; Ross JS
    Mod Pathol; 1997 Aug; 10(8):823-31. PubMed ID: 9267826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.